Gigante Crystal M, Wicker Vaughn, Condori Rene Edgar, Wilkins Kimberly, Li Yu
Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention;
Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention.
J Vis Exp. 2025 May 2(219). doi: 10.3791/66761.
Rabies is a fatal zoonotic disease caused by Lyssavirus rabies (RABV) and related negative strand RNA viruses from the Lyssavirus genus (family Rhabdoviridae). The LN34 assay targets the highly conserved leader region and nucleoprotein gene of the lyssavirus genome and utilizes degenerate primers and a TaqMan probe containing locked nucleotides to detect RNA across the diverse Lyssavirus genus. A negative finding for rabies should be made only if a full cross-section of the brain stem and three lobes of the cerebellum are examined; however, identification of lyssavirus RNA in any tissue is diagnostic of rabies infection. Tissue is collected and homogenized in TRIzol reagent, which also inactivates the virus. RNA extraction is performed using a spin column-based commercial extraction kit. Master mixes are prepared in a clean space and aliquoted into a 96 well plate before adding sample RNA. In clinical settings, each sample is tested by real-time RT-PCR for the presence of lyssavirus RNA in triplicate and singly for host β -actin mRNA. Positive and negative controls are included at extraction and real-time RT-PCR steps of the protocol. Data analysis involves manual adjustment of the thresholds to standardize Ct values across instrument runs. Positive results are determined by the presence of typical amplification in the pan-lyssavirus assay (Ct ≤ 35). Negative results are determined by the absence of typical amplification in the pan-lyssavirus assay and detection of host β-actin mRNA (Ct ≤ 33). Observation of values outside of these ranges or failure of the assay controls can invalidate the run or result in inconclusive results for a specimen. The protocol should be closely followed to ensure high assay sensitivity and specificity. Procedural modifications can affect assay performance and lead to false positive, false negative, or uninterpretable results.
狂犬病是由狂犬病病毒(RABV)以及来自狂犬病毒属(弹状病毒科)的相关负链RNA病毒引起的一种致命性人畜共患病。LN34检测针对狂犬病毒基因组中高度保守的前导区和核蛋白基因,利用简并引物和含锁定核苷酸的TaqMan探针来检测狂犬病毒属内不同病毒的RNA。只有在检查了脑干的完整横截面和小脑的三个叶时,才能得出狂犬病阴性结果;然而,在任何组织中鉴定出狂犬病毒RNA即可诊断为狂犬病感染。组织采集后在TRIzol试剂中匀浆,该试剂也可使病毒失活。使用基于离心柱的商业提取试剂盒进行RNA提取。在洁净空间制备预混液,在加入样品RNA之前将其分装到96孔板中。在临床环境中,每个样品通过实时RT-PCR一式三份检测狂犬病毒RNA的存在情况,并单独检测宿主β-肌动蛋白mRNA。在该方案的提取和实时RT-PCR步骤中均包含阳性和阴性对照。数据分析涉及手动调整阈值,以标准化不同仪器运行间的Ct值。通过泛狂犬病毒检测中典型扩增的存在(Ct≤35)来确定阳性结果。通过泛狂犬病毒检测中无典型扩增以及宿主β-肌动蛋白mRNA的检测(Ct≤33)来确定阴性结果。观察到这些范围之外的值或检测对照失败可能会使检测无效或导致样本结果不确定。应严格遵循该方案以确保检测具有高灵敏度和特异性。程序修改可能会影响检测性能并导致假阳性、假阴性或无法解释的结果。